CSPC Pharmaceutical Group (1093) investor relations material

Executive summary

• Revenue for the first half of 2026 surged 40.1% year-over-year to RMB 18,594 million, driven by robust finished drug sales and a significant increase in licence fee income.

• Net profit attributable to shareholders soared 139.2% year-over-year to RMB 6,094 million, with underlying profit up 165.8% to RMB 6,164 million.

• Gross profit margin increased by 10.6 percentage points to 76.2%, reflecting a higher proportion of finished drug revenue.

• Interim dividend declared at HKD 0.18 per share, up 28.6% from the prior year, with RMB 321 million spent on share buybacks for incentive plans.

• Major out-licensing transactions and global partnerships, including a joint venture and licensing deals with AstraZeneca, contributed to growth.

Financial highlights

• Finished drug revenue grew 56.7% year-over-year to RMB 16,061 million, with licence fee income up 448.5% to RMB 5,895 million.

• Bulk product revenue declined 20.0% to RMB 1,660 million; functional food and others fell 8.2% to RMB 873 million.

• Operating cash inflow reached RMB 10,890 million, up from RMB 3,187 million a year ago.

• R&D expenses rose 12.9% to RMB 3,029 million, representing 29.8% of finished drug revenue (excluding licence fees).

• Basic EPS increased 139.8% to RMB 53.45 cents.

Outlook and guidance

• Continued focus on technological innovation and internationalisation, leveraging AI-driven R&D and global partnerships.

• Over 50 IND approvals expected for the full year, with more than 15 key clinical data readouts in H2 2026.

• Pipeline includes over 200 innovative drugs and preparations, with multiple products in late-stage clinical development.

• Strategic collaborations with AstraZeneca expected to drive future growth and global expansion.

• BD milestone payments are expected to become a recurring income stream.